SeekingAlpha · Mar 2, 2026
NASDAQ · BMEA
Biomea Fusion, Inc.
Healthcare · Biotechnology
$1.74
Down-$0.06 (-3.33%)
Updated Sep 17, 2026, 8:45 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 90.43M
- P/E ratio
- -1.15
- Dividend yield
- 0.00%
- 52-week range
- $1.07 – $2.24
- Volume
- 1.6M
- Avg. volume
- 2.04M
Price performance
BMEA price history
1M range · 0 trading sessions · Daily adjusted prices
BMEA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BMEA news
The latest Smart Investors Daily articles mentioning BMEA.
Stock researchCompany · Overview
BMEA research
Overview
Company profile and research snapshot.
Company profile
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.20
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 5, 2026 | Citizens | Market Outperform | — |
| Apr 28, 2026 | D. Boral Capital | Buy | — |
| Apr 8, 2026 | D. Boral Capital | Buy | — |
| Mar 27, 2026 | Citigroup | Buy | — |
| Mar 25, 2026 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Feb 27, 2026
Biomea Fusion Spotlights Durable Diabetes Data, Oral GLP-1 Weight-Loss Program at Oppenheimer Conf.
Biomea Fusion (NASDAQ:BMEA) outlined progress on its clinical-stage pipeline during an Oppenheimer virtual conference appearance featuring CEO Mick Hitchcock and COO Ramses Erdtmann. The company discussed two lead programs: icovamenib, an oral small-molecule menin inhibitor being developed for diabe
SeekingAlpha · Jan 16, 2026
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-16. The following slide deck was published by Biomea Fusion, Inc.
SeekingAlpha · Jan 15, 2026
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
